Please check your internet connection and try again.
# Ecospirin (Aspirin Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis. Enteric coating delays dissolution until the drug reaches the small intestine, reducing gastric irritation.
## Primary Indications
* **Cardiovascular Risk Reduction:** Primary and secondary prevention of cardiovascular events (e.g., myocardial infarction, stroke) in patients at risk.
* **Pain and Inflammation:** Mild to moderate pain, fever, and inflammatory conditions (less common indication for enteric-coated due to slower onset).
## Adult Dosing
* **Cardiovascular Prophylaxis:**
* **Primary Prevention:** 75 mg to 150 mg once daily. The decision to initiate primary prevention should be individualized based on cardiovascular risk assessment.
* **Secondary Prevention:** 75 mg to 325 mg once daily. Higher doses (e.g., 325 mg) may be used initially after an acute event, then reduced to a lower maintenance dose.
* **Pain/Inflammation (less common for enteric-coated):** Typically 325 mg to 650 mg every 4 to 6 hours as needed. Maximum daily dose is generally 4000 mg, but lower doses are preferred for chronic use and cardiovascular indications.
## Pediatric Dosing
* **Pain and Fever:** Dosing is not well-established for children and adolescents due to the risk of Reye's syndrome. Aspirin should generally be avoided in children and teenagers with viral illnesses (e.g., influenza, chickenpox). If aspirin is deemed necessary under strict medical supervision, specific pediatric dosing guidelines must be followed, which vary by indication and age/weight.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be considered.
* **Renal Impairment:** Use with caution. Dose reduction may be necessary, especially in severe impairment.
* **Elderly:** Increased risk of GI bleeding and renal toxicity. Use the lowest effective dose.
## Contraindications
* Known hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* Asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
* Active peptic ulceration or gastrointestinal bleeding.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Severe hepatic impairment.
* Severe renal impairment.
* Severe heart failure.
* Concomitant use with methotrexate at doses > 20 mg/week.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, gastritis, GI ulcers, GI bleeding (can be severe and life-threatening).
* **Hemorrhagic:** Increased bleeding tendency, bruising, epistaxis, petechiae.
* **Hypersensitivity:** Bronchospasm, urticaria, angioedema, anaphylaxis.
* **Renal:** Renal insufficiency, interstitial nephritis.
* **Auditory:** Tinnitus, hearing loss (often dose-related).
* **Reye's Syndrome:** In children and adolescents with viral infections.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding. Monitor INR/coagulation parameters closely.
* **Other NSAIDs:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **SSRIs/SNRIs:** Increased risk of bleeding, particularly GI bleeding.
* **Alcohol:** Increased risk of GI irritation and bleeding.
* **Methotrexate:** Aspirin can decrease methotrexate clearance, increasing toxicity. Avoid co-administration at high-dose methotrexate regimens.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** Aspirin may reduce their efficacy. Increased risk of renal impairment.
* **Uricosuric agents (e.g., probenecid):** Aspirin can antagonize the uricosuric effect.
## Monitoring
* **GI Bleeding:** Monitor for signs and symptoms (melena, hematemesis, abdominal pain).
* **Bleeding:** Monitor for easy bruising, prolonged bleeding from cuts, epistaxis.
* **Renal Function:** Baseline and periodic monitoring of serum creatinine and BUN, especially in those with risk factors.
* **Hepatic Function:** Baseline and periodic monitoring of LFTs, especially in those with pre-existing liver disease.
* **Tinnitus/Hearing:** Assess for auditory changes, which may indicate toxicity.
## Clinical Pearls
* The enteric coating is designed to bypass the stomach; do not crush, chew, or break the tablets, as this will destroy the coating and increase gastric irritation.
* For acute cardiovascular events (e.g., suspected MI), non-enteric coated aspirin chewed rapidly provides faster absorption.
* Aspirin's antiplatelet effect is irreversible and lasts for the life of the platelet (7-10 days).
* Consider concomitant gastroprotective agents (e.g., PPIs) for patients at high risk of GI bleeding.
* Discontinue aspirin at least 5-7 days before elective surgery, if possible, to minimize bleeding risk.
***
*This information is intended for healthcare professionals and does not replace the need to consult the most current prescribing information and clinical guidelines.*
